Prime Medicine receives FDA clearance for AATD gene therapy
AI Summary
Prime Medicine has received FDA clearance for its gene therapy targeting Alpha-1 Antitrypsin Deficiency (AATD). This regulatory approval marks an important step forward in addressing genetic diseases through advanced biomedical treatments.